# Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/safety-labeling-changes-implementation-of-section-505o4-of-the-federal-food-drug-and-cosmetic-act/2ee1cd52-3926-4b4e-8acb-2ae6e7eea9c8

> FDA guidance document: Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act. Issue date: July 30, 2013. Get complete insights and analysis.

---

## Details

- Title: Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2013-07-30
- Last Changed: 2021-01-26
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0164">FDA-2011-D-0164</a>

## Related Documents

- [Expedited Programs for Serious Conditions | Drugs and Biologics](https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-serious-conditions-drugs-and-biologics/d49c172d-43db-4e76-a0fd-1f51de9ecff3)
- [CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports](https://www.globalkeysolutions.net/guidances/guidance-document/cmc-postapproval-manufacturing-changes-to-be-documented-in-annual-reports/67341cfe-8a48-4fc7-9817-6f9ed89768cf)
- [User Fee Waivers, Reductions, and Refunds for Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/user-fee-waivers-reductions-and-refunds-for-drug-and-biological-products/ff74c3d1-95d4-4808-9bba-25a26706e7e4)